Predictors of Death and Transplant in Patients With a Mechanical Circulatory Support Device: A Multi-institutional Study

被引:148
作者
Holman, William L. [1 ]
Kormos, Robert L. [2 ]
Naftel, David C. [1 ]
Miller, Marissa A. [3 ]
Pagani, Frank D. [4 ]
Blume, Elizabeth [5 ]
Cleeton, Timothy [6 ]
Koenig, Steven C. [7 ]
Edwards, Leah [8 ]
Kirklin, James K. [1 ]
机构
[1] Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35294 USA
[2] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA
[3] NHLBI, Dept Pediat, Rockville, MD USA
[4] Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA
[5] Childrens Hosp, Boston, MA 02115 USA
[6] Univ Florida, Shands Hosp, Gainesville, FL USA
[7] Univ Louisville, Jewish Hosp, Louisville, KY 40292 USA
[8] United Network Organ Sharing, Richmond, VA USA
关键词
VENTRICULAR ASSIST DEVICES; CLINICAL-TRIAL DESIGN; RISK-FACTORS; SURVIVAL; FAILURE; INFECTION; SELECTION; BRIDGE;
D O I
10.1016/j.healun.2008.10.011
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Background: INTERMACS is a registry of FDA-approved durable mechanical circulatory support (MCS) devices used for the strategies of destination therapy (DT) and bridge to transplantation (BTT) or recovery. This study identifies predictors for death and transplantation based on initial results from INTERMACS. Methods: From June 23, 2006 to December 31, 2007, 420 patients from 75 institutions were prospectively entered into the INTERMACS database in which pre-implant data, indication for MCS device use, adverse events, demographics, hemodynamics, laboratory values and outcomes were recorded. Using competing outcomes methodology, risk factors were identified for the events of death and transplantation. Results: The devices included 314 left ventricular assist devices (LVADs), 5 right VADs (RVADs), 77 biventricular VADs (biVADs) and 24 total artificial hearts (TAHs) for a total of 497 pumps in 420 patients. Among the BTT patients at 6 months, 33% were alive with a device in place, 42% were transplanted, 22% had died, and 3% were explanted for recovery. Among the DT patients at 6 months, 68% were alive with a device in place, 5% were transplanted, 25% had died, and 2% were explanted for recovery. The risk factors identified for death across all patient groups include older age (relative risk [RR] = 1.41, p < 0.001), ascites (RR = 2.04, p = 0.003), increased bilirubin (RR = 1.49,p < 0.05) and INTERMACS Level I (cardiogenic shock) (RR = 1.59,p = 0.02). The most common causes of death were central nervous system (CNS) event (18.3% of deaths), multiple-organ failure (16.4%) and cardiac cause (right ventricular failure and arrhythmias, 15.4%). Conclusions: Cardiogenic shock, advanced age and severe right heart failure manifested as ascites or increased bilirubin are risk factors for death after MCS therapy. BTT patients who require biVAD support have a transplant rate similar to that of LVAD-only patients, but their mortality at 6 and 12 months exceeds that of LVAD-only patients. Consideration should be given to MCS referral before the sequelae of right ventricular failure dominate the advanced heart failure syndrome. J Heart Lung Transplant 2009; 28:44-50. Copyright (C) 2009 by the International Society for Heart and Lung Transplantation.
引用
收藏
页码:44 / 50
页数:7
相关论文
共 20 条
[1]
FDA perspective on clinical trial design for cardiovascular devices [J].
Chen, Eric ;
Sapirstein, Wolf ;
Ahn, Chul ;
Swain, Julie ;
Zuckerman, Bram .
ANNALS OF THORACIC SURGERY, 2006, 82 (03) :773-775
[2]
Mechanical circulatory support device database of the International Society for Heart and Lung Transplantation: Third Annual Report - 2005 [J].
Deng, MC ;
Edwards, LB ;
Hertz, MI ;
Rowe, AW ;
Keck, BM ;
Kormos, R ;
Naftel, DC ;
Kirklin, JK ;
Taylor, DO .
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2005, 24 (09) :1182-1187
[3]
Deng MC, 2001, CIRCULATION, V103, P231
[4]
Current concepts of thrombosis and infection in artificial organs [J].
Didisheim, P. .
ASAIO Journal, 1994, 40 (02) :230-237
[5]
First use of the Molecular Adsorbent Recirculating System technique on patients with hypoxic liver failure after cardiogenic shock [J].
El Banayosy, A ;
Kizner, L ;
Schueler, V ;
Bergmeier, S ;
Cobaugh, D ;
Koerfer, R .
ASAIO JOURNAL, 2004, 50 (04) :332-337
[6]
Predictors of survival in patients bridged to transplantation with the Thoratec VAD device:: A single-center retrospective study on more than 100 patients [J].
El-Banayosy, A ;
Arusoglu, L ;
Kizner, L ;
Tenderich, G ;
Boethig, D ;
Minami, K ;
Körfer, R .
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2000, 19 (10) :964-968
[7]
FARRAR DJ, 1994, J HEART LUNG TRANSPL, V13, P93
[8]
Multicenter clinical evaluation of the HeartMate vented electric left ventricular assist system in patients awaiting heart transplantation [J].
Frazier, OH ;
Rose, EA ;
Oz, MC ;
Dembitsky, W ;
McCarthy, P ;
Radovancevic, B ;
Poirier, VL ;
Dasse, KA .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2001, 122 (06) :1186-1195
[9]
Preoperative risk factors for right ventricular failure after implantable left ventricular assist device insertion [J].
Fukamachi, K ;
McCarthy, PM ;
Smedira, NG ;
Vargo, RL ;
Starling, RC ;
Young, JB .
ANNALS OF THORACIC SURGERY, 1999, 68 (06) :2181-2184
[10]
Worldwide experience with the MicroMed DeBakey ventricular assist device® as a bridge to transplantation [J].
Goldstein, DJ .
CIRCULATION, 2003, 108 (10) :272-277